A A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Erlotinib (Primary) ; Onalespib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 17 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2018.
- 21 Mar 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2017 as reported by ClinicalTrials.gov.